Скачайте изображение (превью) выбрав качество

320x180 480x360 640x480 1280x720

In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153).

The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median follow-up period was 3.4 years, as the trial was stopped early at a prespecified interim analysis. The primary outcome were major kidney disease events, onset of kidney failure, a 50% reduction of eGFR from baseline or death from kidney related or cardiovascular causes.

Findings showed that the risk of a primary outcome event was 24% lower in the patients who had received semaglutide as compared to those who had received placebo, with similar findings from the kidney-specific outcomes. Confirmatory secondary endpoints also favoured semaglutide over placebo.

Questions:
-What is the importance of the FLOW trial?
-What was the patient population and study design?
-What are the key findings and safety outcomes?
-What are the implications of these findings on clinical practice?
-What are the next steps?

Recorded Remotely from Kensington, 2024.

Visit Radcliffe Cardiology:
Visit Radcliffe Vascular:

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.

Like us on Facebook:
Follow us on X:

Чтобы скачать видео "ADA 24: FLOW Trial: Kidney Outcomes in Patients Treated with Semaglutide" передвинте ползунок вправо